Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If I went along with your wishful thinking it should only be to shareholders of record at each occurrence of spoofing. But I think that is more than fantasy.
We have waited a great deal of time and still no answers from management. I think as a shareholder I am entitled to these facts. Need quarterly conference calls so a proper analyst can ask a real time question with follow up. Instead we get the Big Biz Show. Sad.
Anything I know about wild swings indicates an event. Good or bad.
Not for me. I want a decent shot at real success. Change the management with experienced capable people who have demonstrated an ability to perform. If that still doesn’t work, I will shorten my horizon.
What you see is a total of 1.7 B authorized shares that will more than likely all be put into circulation by the time management gives themselves their bonuses over the next couple of years. The current C shares are converted to common following a three month waiting period. So those shares are being purchased to fund the company with some investors. When they are converted, they show up in the number. The other conversions are warrants that also put shares in circulation. Having angst or concern or a question about what you see is not worth the time. When they finally start making real money the total outstanding shares will be 1.7 Billion. The company did it to themselves and to shareholders. Just a fact.
True about $100B. No argument. But the present team has destroyed value over their tenure. I have witnessed over a decade of excuses. Hold back bonuses and hold them accountable.
An indication of expectations provided by management. To think so many years after Data Lock the paperwork is still not submitted to only ONE of the four RAs. The last excuse was the printers hired. Prior to that all the pages to be scanned. You cannot make it up. Dismiss the top two clowns steering the clown car. The May 10 debacle was my tipping point. Now I can add Oct. Friday the 13th to the list. Two months beyond that milestone now.
Never met a schedule given or implied in over a decade. People need to be held accountable.
You have to scratch your head in bewilderment that these folks are still in charge. Two months late now for a task that should have been finished within a year following TLD. Be thankful spoofing is run by program trading. The capacity of management to execute properly throws shade on their claims.
Just wait for the bonuses prior to the ASM that will occur when? How I miss the prior to COVID announcement that we would have something really significant to hear at that ASM. I am still waiting to be dazzled.
He was not implying what you suggested. Just a fact. He nor I doubt what the investment could be worth.
He didn’t imply any such notion. I am firmly in his camp about missed promises and for me mismanagement. Doesn’t imply I will sell prior to an expected event. History with this management team has proven expected events do not occur when you have been conditioned to expect them. The last Oct. Friday the 13th showed a 45 day outlook was incapable of the management team meeting. And we are 2 months past that point. Incompetence.
Probably because shareholders and the market in general has no idea what the company is about and what they are slated to do over the next year. If management cannot explain this - no one can.
Navid just sold shares for tax purposes. Probably expects a big bonus that he will now have the funds to pay taxes on.
“What if the company is just fighting extremely evil and greedy forces”
Shareholders
The big lie or incompetent to state.
Bold prediction.
Maybe not an ASM by year’s end but I bet bonuses are given prior to year’s end. Malik purchased shares and immediately sold for tax purposes. Bet he wants it for taxes on a bonus issued by the end of year.
So they all get bonuses by Dec 31st and the ASM happens shortly after.
May be true. But we were told almost a year ago partnerships would be struck. Even if only in trials to come may have been implied.
“This is just an observation, but I would imagine the UK submission is being assembled in a way that they can use it for other regulatory bodies as well with minimal tweaking. “
They pretty much implied this after the first 45 day period missed on Oct 13. Begs the question - How come they didn’t consider this 12 months ago. Must be just my foolish point of view of how a company should operate. Always excuses. Last ASM they were scanning over a million pages. If they digitized everything while the data was taken, that nightmare could have been avoided. Next it is the printers. Pick a proper subcontractor to print, you would have avoided the latest excuse.
Very tired of their excuses. Time for new leadership.
Fortunately for you as a new shareholder that you did not experience the last decade of failure to meet any promised time estimates. If they imply the timeframe of soon, expect a year to three years. The past August 45 day schedule will end up more than 90 days. Good product, c(@p managers. Best to hope the top two souls at the top are replaced.
The management team just makes me sick. Never any accountability. They deserve zero bonus. Bunch of dopes. Put in capable executives and the stock would triple or more.
Such f$$& - ups.
“ I believe the publisher was acquired by a bigger publisher, and the bigger publisher found problems with the application, and together with LP and crew, worked to significantly improve the application. “
If this is true, whose fault is it for selecting a sub par publisher in the first place? MANAGEMENT!
Why cut these folks any slack a minute more? Find competent biotech executives in immunotherapy. If this wasn’t obvious on the May 10 debacle it sure is now.
You have been a shareholder for a long time. Me - over a decade. After years of stumbling I finally had to call it out after the May 10 massacre. The top 2 souls need replacement by competent biotech executive.
I would even agree to give them shares if they left.
A clown show. The arguments for and against authorizing their bonus landslide pre ASM are moot. Everyone should know how to vote if taken today.
The was an analyst paper out about a year ago stating expected approval for Australia in late 2024. Granted scheduling slides to the right on the chart but I would expect FDA prior to Australia.
Not a great strategy but here’s to hoping.
They would be doing it today if people could afford the vaccine. In mid 2024 it should be available in the UK but if you have US insurance Americans will be in the same position as they are today. It will finally become a reality for the UK patients. Not until FDA approval will US patients have a chance to get the vaccine and based on Ashkan’s talk it looks like the US rates last on the submission schedule out of the 4 RAs.
I didn’t forget. The rest of my post provided the caveat.
Doubt that. The remaining C shares are probably for management. The conversations of Cs that people hold and this last loan I would “hope” brings them into a substantial revenue period.
But as someone who has been here over a decade does make me question any promise or outlook. As stated we were expecting trial partnerships almost a year ago. I am not saying it will not happen but expectations based on what little we have been offered more than likely becomes years in time.
There are only a few die hard fans of management left on this message board that have been here before data lock.
At least it looks to not include convertible shares.
Could be a step up into production.
Why we struggled this week.
“On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 24 months. Repayments do not start until November 10, 2024.
Following November 10, 2024, the Loan Agreement will be amortized in 12 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.
The funds will be used for the Company’s ongoing business operations.”
Unfortunately, if you didn’t get most of your shares below 20 cents it really doesn’t feel like it. Similar to someone stating how great the economic statistics are while a family struggles paying for food.
You can pick stats and make an argument. The whole saga is bit messier.
Didn’t they say about 2 weeks after the consultants begin. They were supposed to start at the end of October. We are 2 weeks into November and they said we would be notified when it is no longer in the hands of the consultants and in the hands of the printer. We should have notification any day if they didn’t screw up this estimate completely.
The saga continues. The past decade has been watching ten years worth of a made for TV production of waiting. A bit comical. Someday we may get a real explanation of this last post 45 day delay.
I think it could be a good deal having this Advent incestuous connection.
Unfortunately, not knowing the deal for commercial DCVax product is wrong. Management has failed shareholders by hiding what determines our bottom line years from now.
It should be someone’s first question on a quarterly CC.
I found the maintenance phase years after the initial treatment interesting. We do not really discuss that on the message board. I have always used ~$200K and done when calculating revenue in years to come.
So think of where we would have been if they actually filed prior to Oct 13. Probably 2 to 4 moths to go for approval and real sales. Instead they strategically think with 45 more days they can file with more RAs. Couldn’t they have thought about this over a year ago?
I doubt we will ever get the real reason for this extra delay. The printer. Really?
If your logic is the product is worth the aggravation then you stay invested. Many of us have.
What am I? Been long for over a decade. I am critical of management. If you followed my posts over the period I finally expressed my thoughts about management after the May 10 fiasco. HL was way ahead of me. I think there are many others that feel the same.
I good start would be to remake the BOD with more Biotech and BP people. A ex spy isn’t worth the money he is paid. Time to move the company to the next level. Operational.
No reason to flip out. He expressed his opinion. You went after him. Why shouldn’t he respond. He was civil about it.
“ It’s far beyond incomprehensible how they keep missing timelines, but your judgment that it is solely on them, and not unruly external factors, to the point where they will never again have credibility and never change is pointless until all facts are present.”
Correct we do not know. But unable to make a 45 day timeline seems incompetent after saying your documentation was complete. Thinking we will get a full explanation is folly because we never do. I believe things will change with quarterly calls, analysts and operating income. But based on past experience, I would like to experience a more seasoned biotech CEO. This woman is a horror with nothing but excuses. Last ASM didn’t give me much confidence in her ability and it is almost one year later.
Still bucking the XBI over the last 3 months even with the hiccup. Even clocking MRNA since its MRK deal.